<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Noncontraceptive uses of hormonal contraceptives.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American College of Obstetricians and Gynecologists (ACOG). Noncontraceptive uses of hormonal contraceptives. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2010 Jan. 13 p.&amp;nbsp;(ACOG practice bulletin; no. 110).&amp;nbsp; [160 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Dysmenorrhea  (625.3); Endometriosis, site unspecified  (617.9); Excessive or frequent menstruation  (626.2); Hirsutism  (704.1); Leiomyoma of uterus, unspecified  (218.9); Malignant neoplasm of colon, unspecified site  (153.9); Malignant neoplasm of corpus uteri, except isthmus  (182.0); Malignant neoplasm of ovary  (183.0); Malignant neoplasm of rectum  (154.1); Menstrual migraine, without mention of intractable migraine without mention of status migrainosus  (346.40); Osteoporosis, unspecified  (733.00); Other acne  (706.1); Other disorders of menstruation and other abnormal bleeding from female genital tract  (626.8); Premenstrual tension syndromes  (625.4); Senile osteoporosis  (733.01); Unspecified disorders of menstruation and other abnormal bleeding from female genital tract  (626.9)"/><FieldValue Value="MSH: Acne Vulgaris ; Colorectal Neoplasms ; Contraceptive Agents ; Contraceptive Agents, Female ; Contraceptives, Oral, Combined ; Contraceptives, Oral, Hormonal ; Dysmenorrhea ; Endometrial Neoplasms ; Endometriosis ; Estrogen Replacement Therapy ; Estrogens ; Hirsutism ; Intrauterine Devices, Medicated ; Leiomyoma ; Levonorgestrel ; Medroxyprogesterone Acetate ; Menorrhagia ; Menstruation Disturbances ; Migraine Disorders ; Osteoporosis ; Osteoporosis, Postmenopausal ; Ovarian Neoplasms ; Premenstrual Syndrome ; Progestins ; Risk Factors "/><FieldValue Value="MTH: Acne Vulgaris ; Combined Oral Contraceptives ; Contraceptive Agents ; Dysmenorrhea ; Endometriosis ; Estrogen Replacement Therapy ; Estrogens ; Fibroid Tumor ; Hirsutism ; Malignant neoplasm of ovary ; Malignant Rectal Neoplasm ; Malignant tumor of colon ; medroxyprogesterone acetate ; Menorrhagia ; Menstruation Disturbances ; Migraine Disorders ; Osteoporosis ; Osteoporosis, Postmenopausal ; Osteoporosis, Senile ; ovarian neoplasm ; Polymenorrhagia ; PREMENSTRUAL SYNDROME ; Premenstrual Tension ; Progestins ; risk factors ; Unspecified disorders of menstruation and other abnormal bleeding from female genital tract ; Uterine Fibroids "/><FieldValue Value="PDQ: osteoporosis ; uterine leiomyomata "/><FieldValue Value="SNOMEDCT_US: Acne vulgaris  (88616000); Combined oral contraceptive  (346388008); Contraceptive agent  (108899006); Contraceptive agent  (417122000); Disorder of menstruation  (289896006); Disorder of menstruation  (386804004); Dysmenorrhea  (266599000); Dysmenorrhea  (289900009); Dysmenorrhea  (431416001); Endometriosis  (129103003); Endometriosis  (396224008); Estrogen  (41598000); Estrogen  (61946003); Excessive and frequent menstruation  (266601003); Hirsutism  (399939002); Leiomyofibroma  (702978006); Levonorgestrel  (109032009); Levonorgestrel  (126109000); Malignant neoplasm of corpus uteri, excluding isthmus  (188189001); Malignant tumor of colon  (363406005); Malignant tumor of ovary  (363443007); Malignant tumor of rectum  (363351006); Medroxyprogesterone acetate  (126112002); Medroxyprogesterone acetate  (27707001); Menorrhagia  (386692008); Migraine  (37796009); Neoplasm of endometrium  (123844007); Neoplasm of large intestine  (126837005); Neoplasm of ovary  (123843001); Osteoporosis  (64859006); Postmenopausal osteoporosis  (102447009); Postmenopausal osteoporosis  (32369003); Premenstrual tension syndrome  (82639001); Progestogen  (116614001); Progestogen  (20249007); Risk factor  (80943009); Senile osteoporosis  (18040001); Uterine leiomyoma  (44598004); Uterine leiomyoma  (95315005)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Menstrual cycle irregularity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Menorrhagia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dysmenorrhea &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Premenstrual syndrome &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Menstrual migraines &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk factors for endometrial cancer, ovarian cancer, or colorectal cancer &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acne &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hirsutism &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Osteoporosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Leiomyomas &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Endometriosis &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Assessment of Therapeutic Effectiveness" /><FieldValue Value="Prevention" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Dermatology" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Oncology" /><FieldValue Value="Preventive Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To describe noncontraceptive uses for hormonal contraceptives and examine the evidence evaluating the effectiveness of contraceptives for these applications&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Women at risk for or with conditions that might benefit from noncontraceptive use of hormonal contraceptive drugs&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Use of hormonal contraceptives &lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Estrogen therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Progestin therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Combination therapy (monophasic and triphasic) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Incidence and intensity of pain &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of endometrial, ovarian, or colorectal cancer; leiomyomas; or ovarian cysts &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of bone fractures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment side effects &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Periodicity of menstrual cycle and ovulation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Frequency and degree of&amp;nbsp;menstrual bleeding &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Frequency and degree of migraine headaches &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The MEDLINE database, the Cochrane Library, and the American College of Obstetricians and Gynecologists' own internal resources and documents were used to conduct a literature search to locate relevant articles published between January 1995 and November 2007. The search was restricted to articles published in the English language. Priority was given to articles reporting results of original research, although review articles and commentaries also were consulted. Abstracts of research presented at symposia and scientific conferences were not considered adequate for inclusion in this document. Guidelines published by organizations or institutions such as the National Institutes of Health and the American College of Obstetricians and Gynecologists were reviewed, and additional studies were located by reviewing bibliographies of identified articles.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt;: Evidence obtained from at least one properly designed randomized controlled trial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-1&lt;/strong&gt;: Evidence obtained from well-designed controlled trials without randomization.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-2&lt;/strong&gt;: Evidence obtained from well-designed cohort or case&amp;ndash;control analytic studies, preferably from more than one center or research group.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-3&lt;/strong&gt;: Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III&lt;/strong&gt;: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Analysis of available evidence was given priority in formulating recommendations. When reliable research was not available, expert opinions from obstetrician&amp;ndash;gynecologists were used. See also the &quot;Rating Scheme for the Strength of Recommendations&quot; field regarding Grade C recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Based on the highest level of evidence found in the data, recommendations are provided and graded according to the following categories:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A&lt;/strong&gt;&amp;mdash;Recommendations are based on good and consistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B&lt;/strong&gt;&amp;mdash;Recommendations are based on limited or inconsistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C&lt;/strong&gt;&amp;mdash;Recommendations are based primarily on consensus and expert opinion.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed; however, the cost-effectiveness for the management of menorrhagia was reviewed. Markov modeling has been used to estimate the cost-effectiveness of different approaches to management of menorrhagia in women desiring contraception. In the absence of a pathological cause, the use of a combined oral contraceptive (OC) for menorrhagia was the most cost-effective approach in the first year only. In women who responded initially to a combined OC, it was more cost-effective to switch to a levonorgestrel device than to continue with combined OCs. In women who failed to respond to combined OCs, the levonorgestrel intrauterine system was the most cost-effective approach followed by surgery if the levonorgestrel intrauterine system also failed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Practice Bulletins are validated by two internal clinical review panels composed of practicing obstetrician&amp;ndash;gynecologists generalists and sub-specialists. The final guidelines are also reviewed and approved by the American College of Obstetricians and Gynecologists (ACOG) Executive Board.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The grades of evidence (I&amp;ndash;III) and levels of recommendations (A&amp;ndash;C) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;The following recommendations are based on good and consistent scientific evidence (Level A)&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Combined oral contraceptives (OCs) should not be used to treat existing functional ovarian cysts. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of combined hormonal contraception has been shown to decrease the risk of endometrial and ovarian cancer. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Combined OCs have been shown to regulate and reduce menstrual bleeding, treat dysmenorrhea, reduce premenstrual dysphoric disorder symptoms, and ameliorate acne. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Continuous combined hormonal contraception, depot medroxyprogesterone acetate (DMPA), and the levonorgestrel intrauterine system may be considered for long-term menstrual suppression. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;The following recommendations are based on limited or inconsistent scientific evidence (Level B)&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Based on the limited data available, it appears overall that combined OCs do not increase the risk of development of uterine leiomyomas. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hormonal contraception should be considered for the treatment of menorrhagia in women who may desire further pregnancies. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grades of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt;: Evidence obtained from at least one properly designed randomized controlled trial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-1&lt;/strong&gt;: Evidence obtained from well-designed controlled trials without randomization.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-2&lt;/strong&gt;: Evidence obtained from well-designed cohort or case&amp;ndash;control analytic studies, preferably from more than one center or research group.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-3&lt;/strong&gt;: Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III&lt;/strong&gt;: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A&lt;/strong&gt;&amp;mdash;Recommendations are based on good and consistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B&lt;/strong&gt;&amp;mdash;Recommendations are based on limited or inconsistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C&lt;/strong&gt;&amp;mdash;Recommendations are based primarily on consensus and expert opinion.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Potential Noncontraceptive Benefits of Hormonal Contraception&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Menstrual cycle regularity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of menorrhagia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of dysmenorrhea &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inducing amenorrhea for lifestyle considerations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of premenstrual syndrome &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prevention of menstrual migraines &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Decrease in risk of endometrial cancer, ovarian cancer, and colorectal cancer &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of acne or hirsutism &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Improved bone mineral density &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of bleeding due to leiomyomas &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of pelvic pain due to endometriosis &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Potential side effects of hormonal contraceptive use (e.g., cerebrovascular events)&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The information is designed to aid practitioners in making decisions about appropriate obstetric and gynecologic care. These guidelines should not be construed as dictating an exclusive course of treatment or procedure. Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to the institution or type of practice.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Proposed Performance Measure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Percentage of women using hormonal contraception for symptomatic relief of menorrhagia or dysmenorrhea or both who have no contraindications and wish to preserve reproductive function&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /><FieldValue Value="Patient Resources" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American College of Obstetricians and Gynecologists (ACOG). Noncontraceptive uses of hormonal contraceptives. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2010 Jan. 13 p.&amp;nbsp;(ACOG practice bulletin; no. 110).&amp;nbsp; [160 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 Jan" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American College of Obstetricians and Gynecologists - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American College of Obstetricians and Gynecologists (ACOG)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American College of Obstetricians and Gynecologists (ACOG) committees are created or abolished and their overall function defined by the Executive Board. Appointments are made for one year, with the understanding that such appointment may be continued for a total of three years. The majority of committee members are Fellows, but Junior Fellows also are eligible for appointment. Some committees may have representatives from other organizations when this is particularly appropriate to committee activities. The president elect appoints committee members annually.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: None available&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available for purchase from the American College of Obstetricians and Gynecologists (ACOG) Distribution Center, PO Box 933104, Atlanta, GA 31193-3104; telephone, 800-762-2264, ext. 192; e-mail: &lt;a href=&quot;mailto:sales@acog.org&quot;&gt;sales@acog.org&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The ACOG Bookstore is available online at the &lt;a href=&quot;http://www.acog.org/bookstore/&quot; title=&quot;ACOG Web site&quot; target=&quot;_blank&quot;&gt;ACOG Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Proposed performance measures are included in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Hormonal birth control. Atlanta (GA): American College of Obstetricians and Gynecologists (ACOG); 2007. Available from the &lt;a href=&quot;http://www.acog.org/publications/patient_education/bp159.cfm&quot; title=&quot;ACOG Web site&quot; target=&quot;_blank&quot;&gt;ACOG Web site&lt;/a&gt;. Copies are also available in &lt;a href=&quot;http://www.acog.org/publications/patient_education/sp159.cfm&quot; title=&quot;ACOG Web site&quot; target=&quot;_blank&quot;&gt;Spanish&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on June 7, 2010.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
